LENSAR, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LENSAR, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.44M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $53.49M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $42.16M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $35.36M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $34.46M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $26.38M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $30.53M | Mar 12, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.66M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $45.96M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $35.72M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $29.44M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $29.49M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $22.78M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $26.35M | Mar 12, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($34.28M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($31.40M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($14.38M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($19.91M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | ($19.60M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($19.77M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | ($14.66M) | Mar 12, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($24.58M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($10.67M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($12.23M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($20.18M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | ($19.65M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($18.50M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | ($12.71M) | Mar 12, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.62M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.33M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $6.14M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $11.81M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $12.36M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $7.55M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $7.57M | Mar 12, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.16M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $26.49M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $26.10M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $27.17M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $23.89M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $23.77M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $17.15M | Mar 12, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.83M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($2.28M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($9.66M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($14.86M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | ($8.97M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($13.79M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | ($12.59M) | Mar 12, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $83.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $156.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $236.0K | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $115.0K | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $354.0K | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $366.0K | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $389.0K | Mar 12, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.43M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $66.30M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $69.59M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $55.84M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $66.47M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $79.12M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $34.54M | Mar 12, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $83.67M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $47.65M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $22.41M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $13.86M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $11.59M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $11.91M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $65.09M | Mar 12, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($26.02M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.86M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $33.43M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $41.98M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $54.88M | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | $67.21M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($30.55M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | ($20.47M) | Mar 12, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($177.58M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($143.30M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($111.89M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($97.51M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | ($77.59M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($57.99M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | ($38.19M) | Mar 12, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.97M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $16.26M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $20.62M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $14.67M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $31.64M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $40.60M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $4.62M | Mar 12, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 16, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 16, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11.99M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 11.65M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 11.33M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 11.09M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | 10.99M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 10.93M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | 1.07M | Mar 12, 2021 |